[Only registered and activated users can see links. Click Here To Register...] 9 years, including blinded follow up on 8, 306 women with an intact uterus at randomization in the NSABP P 1 risk reduction trial, the incidence of both adenocarcinomas and rare uterine sarcomas was increased in women taking Tamofen tamoxifen citrate
